UPMC Implements Oracle Health Sciences Translational Research Center to Advance Personalized Medicine; Yields Important Insight into Breast Cancer Just Months After Launch of Five-Year Initiative
(M2 PressWIRE Via Acquire Media NewsEdge) Redwood Shores, Calif. -- Health sciences organizations are focused on realizing the promise of personalized medicine in their quest to develop more effective and efficient treatments for some of the world's most complex diseases. UPMC is using solutions as a key part of the foundation for its five-year, $100 million healthcare analytics initiative, which is yielding important insights into breast cancer just months after its launch.
UPMC , a $10 billion integrated global health enterprise headquartered in Pittsburgh, deployed Oracle Health Sciences solutions to power its enterprise healthcare analytics initiative launched in late 2012.
The initiative is bringing together clinical, genomic, financial, administrative and operational data from more than 200 sources from within UPMC, its health plan and other entities to drive more personalized care and better patient outcomes.
Using Oracle Health Sciences Translational Research Center , UPMC researchers recently integrated and analyzed clinical and genomic information from internal systems as well as from public domain data sources, such as The Cancer Genome Atlas (TCGA).
This work identified genes and pathways unique to pre- and post-menopausal breast cancer. While fully understanding those differences requires additional research, the findings may lead to an ability to change the way patients are treated based on their age.
UPMC uses Oracle Exadata Database Machine as the hardware foundation for its analytical environment and is benefitting from the engineered solution's unmatched scalability, performance and return on investment.
"Just eight months into our five-year healthcare analytics initiative, using Oracle Health Sciences Translational Research Center, we were able to identify molecular differences in breast cancers that may lead to new breakthroughs in treatments and outcomes moving forward. This early insight fuels our excitement about the potential of this important healthcare analytics initiative," said Steven D. Shapiro, M.D., chief medical and scientific officer of UPMC.
"The ability of health sciences organizations, like UPMC, to now fully use the vast quantities of clinical, genetic, molecular and operational data available to drive new insights is key to advancing personalized medicine," said Kris Joshi, vice president, Oracle Health Sciences. "Oracle, through its health sciences applications and core technologies, is honored to be part of UPMC's ground-breaking healthcare analytics initiative."
Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle (NYSE:ORCL), visit www.oracle.com.
About Oracle Health Sciences
At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. Oracle Health Sciences delivers comprehensive business applications, plus database, middleware, and hardware solutions for life sciences and healthcare companies and institutions worldwide. For more information, visit http://www.oracle.com/us/industries/health-sciences/index.html
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
O'Keeffe & Company
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com)).
(c) 2013 M2 COMMUNICATIONS
[ Back To Technology News's Homepage ]